A notable evolution in recent clinical development is the strategic use of GLP-1 RAs as a platform for combinatorial therapy, particularly in the treatment of obesity and metabolic syndrome. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.